{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:09:13Z","timestamp":1781118553358,"version":"3.54.1"},"reference-count":54,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"S\u00e3o Paulo Research Foundation","doi-asserted-by":"publisher","award":["2019\/18034-5"],"award-info":[{"award-number":["2019\/18034-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Background: Although Alcohol Use Disorder (AUD) is highly prevalent worldwide, treating this condition remains challenging. Further, potential treatments for AUD do not fully address alcohol-induced neuroadaptive changes. Understanding the effects of pharmacotherapies for AUD on the human brain may lead to tailored, more effective treatments, and improved individual clinical outcomes. Objectives: We systematically reviewed the literature for studies investigating pharmacotherapies for AUD that included neuroimaging-based treatment outcomes. We searched the PubMed, Scielo, and PsycINFO databases up to January 2021. Study eligibility criteria, participants, and interventions: Eligible studies included those investigating pharmacotherapies for AUD and employing functional magnetic resonance imaging (fMRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), and\/or proton magnetic resonance spectroscopy (H-MRS). Study appraisal and synthesis methods: Two independent reviewers screened studies\u2019 titles and abstracts for inclusion. Data extraction forms were shared among all the authors to standardize data collection. We gathered information on the following variables: sample size; mean age; sociodemographic and clinical characteristics; alcohol use status; study design and methodology; main neuroimaging findings and brain-regions of interest (i.e., brain areas activated by alcohol use and possible pharmacological interactions); and limitations of each study. Results: Out of 177 studies selected, 20 studies provided relevant data for the research topic. Findings indicate that: (1) Acamprosate and gabapentin may selectively modulate limbic regions and the anterior cingulate cortex; (2) Naltrexone and disulfiram effects may involve prefrontal, premotor, and cerebellar regions; (3) Pharmacotherapies acting on glutamate and GABA neurotransmission involve primarily areas underpinning reward and negative affective states, and; (4) Pharmacotherapies acting on opioid and dopamine systems may affect areas responsible for the cognitive and motor factors of AUD. Limitations: Most of the studies were focused on naltrexone. A small number of studies investigated the action of disulfiram and gabapentin, and no neuroimaging studies investigated topiramate. In addition, the time between medication and neuroimaging scans varied widely across studies. Conclusions: We identified key-brain regions modulated by treatments available for AUD. Some of the regions modulated by naltrexone are not specific to the brain reward system, such as the parahippocampal gyrus (temporal lobe), parietal and occipital lobes. Other treatments also modulate not specific regions of the reward system, but play a role in the addictive behaviors, including the insula and dorsolateral prefrontal cortex. The role of these brain regions in mediating the AUD pharmacotherapy response warrants investigation in future research studies.<\/jats:p>","DOI":"10.3390\/brainsci12030386","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T03:06:10Z","timestamp":1647313570000},"page":"386","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Brain Correlates of the Alcohol Use Disorder Pharmacotherapy Response: A Systematic Review of Neuroimaging Studies"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5515-9236","authenticated-orcid":false,"given":"Luiza","family":"Florence","sequence":"first","affiliation":[{"name":"Department of Neuroscience, FMABC University Center, Santo Andr\u00e9 09060-870, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7024-5623","authenticated-orcid":false,"given":"D\u00e2ngela Layne Silva","family":"Lassi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical School, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme T.","family":"Kortas","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical School, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-3562","authenticated-orcid":false,"given":"Danielle R.","family":"Lima","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical School, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-5101","authenticated-orcid":false,"given":"Cintia","family":"de Azevedo-Marques P\u00e9rico","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, FMABC University Center, Santo Andr\u00e9 09060-870, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur G.","family":"Andrade","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, FMABC University Center, Santo Andr\u00e9 09060-870, SP, Brazil"},{"name":"Department of Psychiatry, Medical School, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3277-7036","authenticated-orcid":false,"given":"Julio","family":"Torales","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National University of Asunci\u00f3n, San Lorenzo 2064, Paraguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3934-7007","authenticated-orcid":false,"given":"Antonio","family":"Ventriglio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4415-5058","authenticated-orcid":false,"given":"Domenico","family":"De Berardis","sequence":"additional","affiliation":[{"name":"Mental Health Center of Giulianova, Asl Teramo, 64021 Giulianova, Italy"},{"name":"Department of Neurosciences and Imaging, University \u201cG. D\u2019Annunzio\u201d Chieti, 66100 Chieti, Italy"},{"name":"International Centre for Education and Research in Neuropsychiatry, University of Samara, 443100 Samara, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o P.","family":"De Aquino","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9621-2291","authenticated-orcid":false,"given":"Jo\u00e3o M.","family":"Castaldelli-Maia","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, FMABC University Center, Santo Andr\u00e9 09060-870, SP, Brazil"},{"name":"Department of Psychiatry, Medical School, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"ref_1","unstructured":"Global Burden of Disease Collaborative Network (2018). Global Burden of Disease Study 2017 (GBD 2017) Results, Institute for Health Metrics and Evaluation (IHME)."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). DSM-5: Diagnostic and Statistical Manual of Mental Disorder, American Psychiatric Publishing. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_3","unstructured":"World Health Organization (2004). ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision, World Health Organization. [2nd ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","article-title":"The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"5","author":"Degenhardt","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMra1511480","article-title":"Neurobiologic Advances from the Brain Disease Model of Addiction","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1111\/acer.14167","article-title":"The Use of Functional Magnetic Resonance Imaging to Test Pharmacotherapies for Alcohol Use Disorder: A Systematic Review","volume":"43","author":"Grodin","year":"2019","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/bs.pbr.2015.07.016","article-title":"PET imaging for addiction medicine: From neural mechanisms to clinical considerations","volume":"224","author":"Wiers","year":"2015","journal-title":"Prog. Brain Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00259-013-2606-5","article-title":"The origins of SPECT and SPECT\/CT","volume":"41","author":"Hutton","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/B978-0-444-62619-6.00019-7","article-title":"Brain proton magnetic resonance spectroscopy of alcohol use disorders","volume":"125","author":"Meyerhoff","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder","volume":"175","author":"Reus","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1590\/S1516-44462004000500011","article-title":"The pharmacologic treatment of the alcohol dependence","volume":"26","author":"Castro","year":"2004","journal-title":"Rev. Bras. Psiquiatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1038\/npp.2017.74","article-title":"Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status","volume":"42","author":"Schacht","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/npp.2012.195","article-title":"Interacting Effects of Naltrexone and OPRM1 and DAT1 Variation on the Neural Response to Alcohol Cues","volume":"38","author":"Schacht","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"ref_15","unstructured":"Center for Substance Abuse Treatment (2009). Incorporating Alcohol Pharmacotherapies Into Medical Practice, Substance Abuse and Mental Health Services Administration (US). Report No.: (SMA) 09-4380."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/JCP.0000000000000590","article-title":"Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients With Alcohol Dependence","volume":"36","author":"Frye","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1530-0277.1998.tb03871.x","article-title":"Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain","volume":"22","author":"Naassila","year":"1998","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fpsyt.2018.00078","article-title":"Brain GABA and Glutamate Concentrations Following Chronic Gabapentin Administration: A Convenience Sample Studied During Early Abstinence From Alcohol","volume":"9","author":"Meyerhoff","year":"2018","journal-title":"Front. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0741-8329(00)00137-3","article-title":"Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption","volume":"23","author":"Stromberg","year":"2001","journal-title":"Alcohol"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-2999(96)00696-6","article-title":"The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal","volume":"317","author":"Putzke","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Skinner, M.D., Lahmek, P., Pham, H., and Aubin, H.-J. (2014). Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087366"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","article-title":"Disulfiram treatment of alcoholism. A Veterans Administration cooperative study","volume":"256","author":"Fuller","year":"1986","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4088\/JCP.v68n1108","article-title":"Gabapentin reduces alcohol consumption and craving: A randomized, double-blind, placebo-controlled trial","volume":"68","author":"Furieri","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.ALC.0000113409.47937.6C","article-title":"Development of Novel Pharmacotherapies for the Treatment of Alcohol Dependence: Focus on Antiepileptics","volume":"28","author":"Johnson","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/01.ALC.0000153542.10188.B0","article-title":"Safety and Efficacy of GABAergic Medications for Treating Alcoholism","volume":"29","author":"Johnson","year":"2005","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1038\/tp.2017.34","article-title":"Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery","volume":"7","author":"Savulich","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1111\/acer.12546","article-title":"Predicting naltrexone response in alcohol-dependent patients: The contribution of functional magnetic resonance imaging","volume":"38","author":"Mann","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archpsyc.65.4.466","article-title":"Effect of Naltrexone and Ondansetron on Alcohol Cue\u2013Induced Activation of the Ventral Striatum in Alcohol-Dependent People","volume":"65","author":"Myrick","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/sj.npp.1301440","article-title":"Differences in \u03b4- and \u03bc-Opioid Receptor Blockade Measured by Positron Emission Tomography in Naltrexone-Treated Recently Abstinent Alcohol-Dependent Subjects","volume":"33","author":"Weerts","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref_30","first-page":"19","article-title":"Regional cerebral blood flow changes in chronic alcoholic patients induced by naltrexone challenge during detoxification","volume":"40","author":"Catafau","year":"1999","journal-title":"J. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/adb.12503","article-title":"Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals","volume":"23","author":"Morris","year":"2017","journal-title":"Addict. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neuroimage.2013.03.055","article-title":"Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: A bold FMRI study","volume":"78","author":"Lukas","year":"2013","journal-title":"NeuroImage"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1111\/acer.12581","article-title":"Effects of Naltrexone on Neural and Subjective Response to Alcohol in Treatment-Seeking Alcohol-Dependent Patients","volume":"38","author":"Spagnolo","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e12717","DOI":"10.1111\/adb.12717","article-title":"Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone","volume":"25","author":"Bach","year":"2019","journal-title":"Addict. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.drugalcdep.2019.02.028","article-title":"Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent","volume":"200","author":"Lim","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/ejn.14262","article-title":"Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals","volume":"50","author":"Nestor","year":"2018","journal-title":"Eur. J. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/JCP.0b013e318267b586","article-title":"The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study","volume":"32","author":"Langosch","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archgenpsychiatry.2010.125","article-title":"Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals a randomized controlled experimental medicine study","volume":"67","author":"Umhau","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/j.1530-0277.1996.tb01149.x","article-title":"Effects of Disulfiram on Positron Emission Tomography and Neuropsychological Studies in Severe Chronic Alcoholism","volume":"20","author":"Gilman","year":"1996","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00213-013-2996-x","article-title":"Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics","volume":"227","author":"Schacht","year":"2013","journal-title":"Psychopharmacology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1176\/appi.ajp.2021.20121757","article-title":"Effects of Gabapentin on Dorsal Anterior Cingulate Cortex GABA and Glutamate Levels and Their Associations With Abstinence in Alcohol Use Disorder: A Randomized Clinical Trial","volume":"178","author":"Prisciandaro","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.biopsych.2019.05.021","article-title":"The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving","volume":"86","author":"Goldberg","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"ref_43","unstructured":"Sadock, B.J., and Sadock, V.A. (2012). Functional neuroanatomy. Kaplan and Sadock\u2019s Comprehensive Textbook of Psychiatry, Lippincott William and Wilkins. [8th ed.]."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3389\/fpsyt.2019.00592","article-title":"Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice","volume":"10","author":"Kakko","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1176\/appi.ajp.159.10.1642","article-title":"Drug Addiction and Its Underlying Neurobiological Basis: Neuroimaging Evidence for the Involvement of the Frontal Cortex","volume":"159","author":"Goldstein","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"530","DOI":"10.5694\/j.1326-5377.2002.tb04550.x","article-title":"Naltrexone in alcohol dependence: A randomised controlled trial of effectiveness in a standard clinical setting","volume":"176","author":"Latt","year":"2002","journal-title":"Med. J. Aust."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1126\/science.1094765","article-title":"Matching Behavior and the Representation of Value in the Parietal Cortex","volume":"304","author":"Sugrue","year":"2004","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drugalcdep.2016.12.028","article-title":"The cerebellum in drug craving","volume":"173","author":"Miquel","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/npp.2011.99","article-title":"Identifying Neurobiological Phenotypes Associated with Alcohol Use Disorder Severity","volume":"36","author":"Claus","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neubiorev.2016.03.034","article-title":"Cortical and subcortical gray matter shrinkage in alcohol-use disorders: A voxel-based meta-analysis","volume":"66","author":"Yang","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/cercor\/bhj088","article-title":"Basal Ganglia Functional Connectivity Based on a Meta-Analysis of 126 Positron Emission Tomography and Functional Magnetic Resonance Imaging Publications","volume":"16","author":"Postuma","year":"2005","journal-title":"Cereb. Cortex"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.tins.2008.09.009","article-title":"The hidden island of addiction: The insula","volume":"32","author":"Naqvi","year":"2009","journal-title":"Trends Neurosci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/12\/3\/386\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:36:02Z","timestamp":1760135762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/12\/3\/386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["brainsci12030386"],"URL":"https:\/\/doi.org\/10.3390\/brainsci12030386","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]}}}